In managing functional dyspepsia, itopride and acotiamide, tricyclic antidepressants, histamine‐2 receptor antagonists, proton pump inhibitors, and the antipsychotic sulpiride or levosulpiride all prove to be more effective than placebo, according to the results of a meta-analysis.
Diabetes, hypertension, and older age are associated with lower hospital readmission in patients with gastroparesis, while higher length of stay (LOS), drug abuse, and marijuana use increase the 30-day readmission rate, a study has shown.
Administering extended doses of mirikizumab for an additional 12 weeks successfully produces a clinical response in up to 50 percent of ulcerative colitis (UC) patients who did not benefit from 12 weeks of induction doses, according to the results of a phase II trial.
Treatment with infliximab to control inflammation effectively reduces parameters that are associated with a higher risk of venous thromboembolism in patients with inflammatory bowel disease (IBD), results of a study have shown.
In the treatment of patients with inflammatory bowel disease (IBD), comorbidities, but not patient age, influence the risk of any infection or hospitalizations on either vedolizumab or ustekinumab, a study suggests.
Patients with inflammatory bowel diseases (IBDs) suffer from higher mortality rates and are at an increased risk of cancer when they develop new-onset primary sclerosing cholangitis, a recent study has found.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.